Tyrosine Kinase Inhibitors Targeted to the Epidermal Growth Factor Receptor Subfamily: Role as Anticancer Agents

ISSN： 0012-6667

Source： Drugs, Vol.59, Iss.4, 2000-04, pp. : 753-767

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Putting the Brakes on Cancer: Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

Pharmaceutical Innovation, Vol. 12, Iss. 1, 2002-12 ,pp. : 12-15

Adis International

Access to resources Recommend Favorite

Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines

By Collins D. Crown J. O’Donovan N. Devery A. O’Sullivan F. O’Driscoll L. Clynes M. O’Connor R.

Investigational New Drugs, Vol. 28, Iss. 4, 2010-08 ,pp. : 433-444

Springer Publishing Company

Access to resources Recommend Favorite

Recent Advancements in Small Molecule Inhibitors of Insulin–like Growth Factor-1 Receptor (IGF-1R) Tyrosine Kinase as Anticancer agents

Mini Reviews in Medicinal Chemistry, Vol. 13, Iss. 5, 2013-04 ,pp. : 653-681

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutically Targeted Anticancer Agents: Inhibitors of Receptor Tyrosine Kinases

Mini Reviews in Medicinal Chemistry, Vol. 4, Iss. 3, 2004-03 ,pp. : 273-283

Bentham Science Publishers

Access to resources Recommend Favorite

Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials

By Ciardiello Fortunato De Vita Ferdinando Orditura Michele De Placido Sabino Tortora Giampaolo

Expert Opinion on Emerging Drugs, Vol. 8, Iss. 2, 2003-11 ,pp. : 501-514

Informa Healthcare

Access to resources Recommend Favorite